Clinical Trial Update: Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults [Phase 1]

View source ↗

Summary

This entry describes a Phase 1 study evaluating the safety and immunogenicity of revaccination with SCB-1019T in healthy adults for respiratory syncytial virus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• SCB-1019T

Snippet

Sponsor: Clover Biopharmaceuticals USA, LLC | Conditions: RSV Infection | Phase 1 | Status: RECRUITING